Effective pulmonary blood flow in children with acute asthma attack requiring hospitalization.
In children with acute obstructive lung disease gas exchange is affected by ventilation-perfusion mismatch and the degree of bronchoconstriction. Standard lung function measurements do not reflect the impairment in gas exchange. Alternatively, the effective pulmonary blood flow (EPBF), that is, the proportion of the cardiac output that is supplying well-ventilated lung units, can give accurate and noninvasive estimates of ventilation-perfusion mismatch. We measured EPBF with the argon freon-22 rebreathing technique in children with acute severe asthma to assess their response to nebulized salbutamol and to determine whether induced changes in the EPBF could be predicted from baseline measurements. Twenty-four children admitted with an acute asthma attack had spirometry and triplicate EPBF measurements before and after nebulized salbutamol. Eighteen patients had repeated tests 50 days later when fully recovered; 4 patients were taking methylxanthines on at least one occasion. The mean forced expiratory volume in 1 sec (FEV1) rose from 55% of predicted to 66% after salbutamol and to 83% with recovery. The mean coefficients of variation for EPBF measurements on the three test occasions were 11.3%, 8.2%, and 9%. Except in children on methylxanthines, the EPBF values were reduced during the acute asthma attack (median, 2.53 L/min/m2; range, 1.99-3.60 L/min/m2) compared with paired values obtained after recovery (median, 2.89 L/min/m2; range, 2.28-4.04 L/min/m2) (P = 0.009). Salbutamol caused a highly significant increase in EPBF from 2.88 L/min/m2 (range, 1.86-3.80) before treatment to 3.34 L/min/m2 (range, 2.26-4.65) immediately afterwards (P = 0.0003).(ABSTRACT TRUNCATED AT 250 WORDS)
Yiallouros
P K
PK
Division of Paediatrics, United Medical School of Guy's Hospital, University of London, England.
Milner
A D
AD
D000208:Acute Disease; D000293:Adolescent; D000336:Aerosols; D000420:Albuterol / Q000494:pharmacology* / Q000627:therapeutic use; D001128:Argon; D001249:Asthma / Q000188:drug therapy / Q000503:physiopathology*; D001993:Bronchodilator Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005617:Chlorofluorocarbons, Methane; D015633:Extravascular Lung Water; D005260:Female; D005541:Forced Expiratory Volume; D005652:Functional Residual Capacity; D006339:Heart Rate; D006760:Hospitalization; D006801:Humans; D008168:Lung / Q000098:blood supply*; D008176:Lung Volume Measurements; D008297:Male; D011659:Pulmonary Gas Exchange / Q000187:drug effects / Q000502:physiology*; D013147:Spirometry; D013318:Stroke Volume / Q000502:physiology; D014970:Xanthines / Q000627:therapeutic use
D000336:Aerosols; D001993:Bronchodilator Agents; D005617:Chlorofluorocarbons, Methane; D014970:Xanthines; C008514:methylxanthine; D001128:Argon; D000420:Albuterol